Hans Warrinnier, chief medical officer at Bioxodes, said in a statement that the results are preliminary but all point in the ...

Bioengineering nonprofit Cultivarium is embarking on a three-year journey to develop tools and resources for scientists ...

Sanofi’s development of an oral spin on Humira’s mechanism has hit a setback. | Sanofi’s development of an oral spin on ...

Granite Bio is ready to rock ‘n’ roll, unveiling with $100 million and hopes of shaping new antibody treatments targeting ...

A new biotech is hitting the Boston scene with $50 million from Flagship Pioneering and a goal of preventing patients from ...

Over the next four months, the Vaccine Integrity Project will hold information-gathering sessions with medical associations, public health organizations, state health officials, vaccine manufacturers, ...

Boston Scientific said that while tariffs pose “unfortunate” headwinds—which are poised to add about $200 million to the cost of doing business this year, according to the company’s estim | Boston ...

A study of almost 34,000 people in rural China has revealed that lowering blood pressure can reduce the risk of dementia in patients with hypertension. | A study of almost 34,000 people in rural China ...

Mosaic Therapeutics has secured the latest pieces in its combination medicine strategy by licensing two clinical stage tumor drugs from fellow British biotech Astex Pharmaceuticals. | Mosaic ...

Big Pharma's M&A plans will likely take a hit if the U.S. government under the Trump administration lives up to its threats of imposing tariffs on the industry, Roche’s CEO has warned. | Big Pharma ...

Vanda Pharmaceuticals is suing the FDA again, this time alleging the agency is unlawfully delaying a hearing to discuss the ...

After selling off a portion of its diabetes care business last year, Ypsomed is now fully exiting the diabetes care business ...